drugset / Trial / NCT01088789
Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer
Phase 2
Active not recruiting
71 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The Skip Viragh Foundation · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and feasibility of long term boost vaccination of a lethally irradiated, allogenic pancreatic tumor cell vaccine transfected with the granulocyte macrophage colony-stimulating factor (GM-CSF) gene (GVAX Pancreas Vaccine) alone or given in combination with either a single intravenous dose or daily metronomic oral doses of cyclophosphamide for the treatment of patients with surgically resected adenocarcinoma of the pancreas.
Timeline
- Start
- 2010-04-20
- Primary completion
- 2024-07-17
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 200 mg/m2 | Intravenous |
| Subject | GVAX Pancreas Vaccine | Vaccine | — | — |